Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064905 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT04064905 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 120 participants.
The verdict
NCT04064905, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants
Interventions
- OTHER Placebo
- BIOLOGICAL mRNA-1893
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2021-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04064905
The ClinicalTrials.gov registry entry for NCT04064905 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04064905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04064905 about?
NCT04064905 is a clinical study titled "Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults". This clinical study will evaluate the safety, tolerability and reactogenicity of mRNA-1893 Zika vaccines in flavivirus seronegative and flavivirus seropositive participants
What is the current status of trial NCT04064905?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2019-07-30. Estimated completion is 2021-03-22.
What interventions are being tested in trial NCT04064905?
The interventions under investigation include: Placebo (OTHER), mRNA-1893 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04064905?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.